Morepen Labs Q3 FY26: Gross Revenue Up 13% to ₹462 Cr
Morepen Laboratories reported Q3 FY26 gross revenue of ₹462 crore, a 13% increase year-on-year. The Pharma business revenue was stable at ₹285 crore, while Medical Devices revenue rose to ₹177 crore. Standalone PAT was ₹8 crore and consolidated PAT was ₹28 crore.
The revenue growth is positive, but the overall financial performance needs further detailed analysis from the full report to determine the extent of its impact.
The company reported a year-on-year increase in gross revenue for the quarter, indicating positive business performance.
Morepen Laboratories Limited has announced its financial results for the third quarter and nine months ended December 31, 2025. The company's gross revenue for Q3 FY26 stood at ₹462 crore, marking a 13% increase compared to ₹408 crore in Q3 FY25. For the nine-month period of FY26, the gross revenue reached ₹1231 crore, up from ₹1185 crore in the corresponding period of FY25.
The Pharma business, comprising API and formulations, contributed ₹285 crore in Q3 FY26, remaining stable compared to ₹285 crore in Q3 FY25. The API segment reported revenue of ₹249 crore in Q3 FY26, a slight decrease from ₹251 crore in Q3 FY25. Formulation revenue was ₹35 crore in Q3 FY26, up from ₹32 crore in Q3 FY25.
The Medical Devices segment generated ₹177 crore in Q3 FY26, an increase from ₹123 crore in Q3 FY25. This segment includes products like thermometers, nebulizers, pregnancy kits, and ortho supports. The company highlighted its leadership in glucometers, with 16.85 million happy customers and 2.33 billion gluco strips sold.
On a standalone basis, the company reported a gross revenue of ₹488 crore in Q3 FY26, an increase from ₹416 crore in Q2 FY26. EBITDA was ₹46 crore and PAT was ₹8 crore. Consolidated gross revenue for Q3 FY26 was ₹462 crore, with EBITDA at ₹50 crore and PAT at ₹28 crore (net of exceptional income of ₹25.83 crore).
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.